Saturday, April 22, 2023 9:49:55 PM
You need real world efficacy of a drug (Data Driven) to prove anything worthwhile ($) in pharmaceuticals. Bellus Health methodically went about the business of doing just that for their shareholders. they didn't spend years wasting money and time chasing rabbits down hellholes in Pennyland. The CEO offers more Lip Service and Hoping Wishing stuff from one year to the next. He simply wants more of your money to dump into his salary and benefits package. He's been very successful at doing just that ever since Calendar Year 2018.
A Data Driven company Algernon Pharmaceuticals is not. You'll see further glaring evidence of that when they pigeonhole another clinical trial in slow roll enrollment rate Australia for "Tax Rebates" received many years later Those at the helm of Algernon Pharmaceuticals are cut from the cloth of Penny Stock operators, through and through (Like The Wolf Of Wall Street). Period.
More Wolf Tickets
M$
P.S. I am not a subscriber of anything coming from Algernon Pharmaceuticals. Thanks for the Heads Up Shell.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM